Stockwinners Market Radar for August 07, 2020 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:10 EDT Microsoft's Courtois sells over 15,000 common shares - In a regulatory filing, Microsoft executive VP Jean Philippe Courtois disclosed the sale of 15,140 common shares of the company on August 6 at a price of $215 per share.

17:32 EDT BAE Systems awarded estimated $144M five-year Air Force contract - BAE Systems has been awarded an estimated $144M five-year firm-fixed-price requirements contract for common avionics and electronic components applicable to B1-B, ASQ-151, APX-113, ALQ-172, USM-464, AN/ALQ-155, ALQ-161, USM-638, B-52 platforms. This contract provides for sustainment of spares/buys, repairs and engineering services related to various systems and components that are sole source to BAE. Work is expected to be completed March 22, 2026. This award is the result of a sole-source acquisition. FY20 Consolidated Sustainment Activity Group funds will be used, but no funds are being obligated at the time of award. Air Force Sustainment Center is the contracting activity.

17:04 EDT ATIF Holdings receives noncompliance notice from Nasdaq - ATIF Holdings announced that it received a written notice from the Listing Qualifications Department of Nasdaq indicating that the company is not in compliance with the Nasdaq listing rules as a result of not having held an annual meeting of stockholders within 12 months of the end of the company's fiscal year on July 31. The notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the company's securities on Nasdaq. The notice states that, under the rules, the company has 45 calendar days to submit a plan to regain compliance with the rules. The company intends to submit a plan to regain compliance with the rules within the required timeframe. If Nasdaq accepts the company's plan, Nasdaq may grant the company an extension of up to 180 calendar days from the company's fiscal year end, or until January 31, 2021, to regain compliance. The company is planning to hold its annual shareholders meeting on November 3.

16:29 EDT ChinaNet Online names Charles Chiu COO - ChinaNet Online Holdings announced the appointment of Charles Chiu to the position of the company's Chief Operating Officer and Mark Li, the current Chief Financial Officer of the company, to serve as Secretary of the company, effective immediately. Mr. George Chu has resigned from the role of Chief Operating Officer and Secretary of the company due to personal reasons. Chu continues to serve as a director of the Board of Directors of the company.

16:17 EDT Pzena Investment reports AUM $32.4B as of July 31st vs. $31.5B prior month

16:11 EDT Flex CFO Chris Collier to resign, Paul Lundstrom to succed - Flex (FLEX) announced that Paul Lundstrom will join the company as CFO on September 1. Lundstrom will succeed Chris Collier, who following a 25-year career and after serving as Flex's CFO for the past seven years, is resigning for personal reasons. Collier will stay on as an employee to support a transition of the CFO position, advise on several business initiatives and serve as a senior advisor to Revathi Advaithi, CEO of Flex for the period commencing on September 1 through March 31, 2021. Lundstrom will report directly to Advaithi and will be based out of the corporate headquarters in San Jose, California. Lundstrom's experience leading finance organizations over the last 20 years in manufacturing and industrial, and background in international markets and operating environment, is aligned with Flex's needs in its transformational strategy for long-term growth. Most recently, Lundstrom has served as VP of finance and CFO of Aerojet Rocketdyne (AJRD).

15:27 EDT Nasdaq schedules trading in SCWorx Corp. to resume on August 10 - The Nasdaq Stock Market announced that trading in SCWorx Corp. (WORX) is scheduled to resume on Monday, August 10, 2020, at 7:00 a.m. Eastern Time. Trading in the company's stock was halted on April 22, 2020 at 9:25:05 a.m. Eastern Time.

14:28 EDT Guardant Health announces FDA approval for Guardant360 CDx for CGP - Guardant Health announces that the U.S. Food and Drug Administration has approved Guardant360 CDx for tumor mutation profiling, also known as comprehensive genomic profiling, or CGP, in patients with any solid malignant neoplasm. The Guardant360 CDx is also approved as a companion diagnostic to identify non-small cell lung cancer patients with epidermal growth factor receptor alterations who may benefit from treatment with Tagrisso. "Guardant360 CDx offers patients and clinicians a simple, faster blood test to help inform personalized treatment options," the company said. "The FDA approval of Guardant360 CDx is a landmark decision, demonstrating the value liquid biopsy delivers to oncologists and more importantly, the patients they treat. Traditional tissue biopsy-based tumor profiling, which is often invasive and has longer turnaround times, can contribute to delays in starting treatment and possibly suboptimal therapy. We applaud the FDA for their collaborative review process and for approving the first comprehensive genomic profiling liquid biopsy test. We are confident that our FDA approval will help accelerate wider adoption of guideline-recommended genomic profiling, increase the number of advanced cancer patients who receive potentially life-changing treatments, and pave the way for new companion diagnostic developments for the Guardant360 CDx," added Guardant Health CEO Helmy Eltoukhy.

14:22 EDT Guardant Health halted, news pending

13:58 EDT PTC wins FDA approval of spinal muscular atrophy treatment Evrysdi - PTC Therapeutics (PTCT) announced that the Food and Drug Administration has approved Evrysdi, the first at-home, orally administered treatment for spinal muscular atrophy in adults and children two months and older. Evrysdi will be available in the United States within two weeks for direct delivery to patients' homes through Accredo Health Group, an Express Scripts specialty pharmacy, PTC noted. Evrysdi will be marketed in the United States by Genentech, a unit of Roche Group (RHHBY). Outside the United States, Roche holds global commercialization rights to risdiplam. Shares of PTC Therapeutics halted for trade up 7% to $50.35.

13:48 EDT Roche announces FDA approval of Evrysdi for Spinal Muscular Atrophy treatment

13:39 EDT Google reports filing supplemental brief in legal case with Oracle - Kent Walker, SVP of Global Affairs, posted to the Google blog, stating in part: "Open software interfaces have been an integral part of the innovation economy. They enable the interoperability that has always let software developers build on each other's work. And the interoperability of open software interfaces is what lets different technologies like apps work together on a variety of devices and platforms: That's why you can take a photo on an Apple phone, save it onto Google's cloud servers, and edit it on a Surface tablet. Our legal case with Oracle turns on our belief that interoperability has been good for innovation, good for developers, and good for consumers... Today, we filed a supplemental brief explaining how the jury in our case heard from over a dozen witnesses, reviewed hundreds of documents, and then unanimously agreed with our position. America's Constitution enshrines the right to a jury trial. The Supreme Court has recognized the important role of a jury in deciding nuanced, fact-specific questions like the ones in this case. A decision in Oracle's favor would limit consumers' freedom to use technologies on a range of devices. It would upend the way developers have always used software interfaces, locking them into existing platforms and giving copyright owners new power to control the building blocks of new technologies. And it would erode the traditional role of the jury in evaluating all the facts relevant to a decision. We look forward to making this case to the Court on October 7." Reference Link

12:17 EDT Amarin announces support for investigator-initiated trial of VASCEPA - Amarin Corporation announced support for an investigator-initiated trial to study the effects of icosapent ethyl on laboratory-confirmed viral upper respiratory infection rates, clinical impact and outcomes, especially with severe acute respiratory syndrome coronavirus 2 infection which causes COVID-19, in adults with established atherosclerotic cardiovascular disease who are at elevated risk of experiencing moderate to severe COVID-19. The trial, dubbed PragMatic randomIzed Trial of Icosapent ethyl for hiGh-cArdiovascular risk adults in The Era of COronaVIrus Disease 2019, is sponsored by Kaiser Permanente Northern California, and is being led by Dr. Andrew P. Ambrosy, Associate Program Director for Research, Department of Cardiology, Kaiser Permanente San Francisco Medical Center, and Dr. Alan S. Go, Regional Medical Director, Clinical Trials Program and Associate Director, Cardiovascular and Metabolic Conditions Research, Division of Research, Kaiser Permanente Northern California. MITIGATE COVID-19 will randomly assign 1500 U.S. patients aged 50 years or older with established ASCVD and no prior history of confirmed COVID-19 to receive 4 grams per day of icosapent ethyl and follow these patients for a minimum of 6 months. The co-primary study endpoints are the rate of moderate to severe laboratory-confirmed viral URI, including COVID-19 and influenza, prompting urgent care encounters, emergency department visits, or hospitalization and the worst clinical status due to a laboratory-confirmed viral URI based on an ordinal scale taking hospitalization, death, supplemental oxygen, and other clinical factors into account. A control group will consist of 15,000 adults meeting the same eligibility criteria who will be passively followed through KPNC's comprehensive and state-of-the-art electronic health record system for outcome ascertainment. Current understanding of the biology of COVID-19 is that patients that have or are at high risk for developing ASCVD are at higher risk of death and severe effects from infection, and that the morbidity and mortality associated with COVID-19 are due both to the direct toxicity of the virus as well as the body's robust inflammatory response leading to 'cytokine storm'. Based on data related to the mechanism of action and effects of VASCEPA, it is hypothesized that VASCEPA may play a potential beneficial role in preventing SARS-CoV-2 infection and to potentially reduce clinical severity in patients infected by the virus. The clinical effects of VASCEPA are multi-factorial. Multiple mechanisms of action associated with VASCEPA based on clinical and mechanistic studies support the rationale to test its effects in patients with or at risk for COVID-19 disease. Some of these postulated mechanisms include the following: Potential antiviral/antimicrobial effects; Fibrosis and cardiac damage mitigation in animal models; Anti-inflammatory effects in pulmonary/lung tissue.

12:01 EDT Illinois Tool Works declares Q3 dividend of $1.14 per share on common stock - The Board declared a dividend on the company's common stock of $1.14 per share for the third quarter of 2020. The dividend equates to $4.56 per share on a full-year basis. The dividend will be paid on Wednesday, October 14, 2020, to shareholders of record as of September 30, 2020.

12:00 EDT Bluegreen Vacations falls -10.5% - Bluegreen Vacations is down -10.5%, or -62c to $5.28.

12:00 EDT Alteryx falls -27.6% - Alteryx is down -27.6%, or -$46.69 to $122.31.

12:00 EDT Teradata rises 18.3% - Teradata is up 18.3%, or $3.78 to $24.47.

11:01 EDT TOP Ships announces 1-for-25 reverse stock split - TOP Ships announced that it has determined to effect a 1-for-25 reverse stock split of the company's issued common shares. The company's shareholders approved the reverse stock split and granted the board the authority to determine the exact split ratio and when to proceed with the reverse stock split at the company's annual meeting of shareholders held on May 29, the company noted. The reverse stock split will take effect, and the company's common stock will begin trading on a split-adjusted basis on the NASDAQ Capital Market, as of the opening of trading on Monday, August 10, under the existing ticker symbol "TOPS," the company announced.

10:32 EDT Kazia Therapeutics receives Rare Pediatric Disease Designation for paxalisb - Kazia Therapeutics announced that the United States Food and Drug Administration has awarded Rare Pediatric Disease Designation to Kazia's paxalisib for the treatment of Diffuse Intrinsic Pontine Glioma, a rare and highly-aggressive childhood brain cancer. RPDD has been awarded following positive emerging preclinical data in DIPG, and with initial clinical efficacy data expected in 2H CY2020; positive clinical data may substantially enhance likelihood of a potential future PRV.

10:05 EDT Morgan Stanley GSE named Institutional Financial Advisor for NFLPA - Morgan Stanley said in a release, "Morgan Stanley Global Sports & Entertainment, or GSE, has been named an official Institutional Financial Advisor participant of the NFL Players Association, or NFLPA, the official labor union for professional football players in the National Football League. In an effort to address the financial needs of its participating athletes, the NFLPA launched its Institutional Financial Advisors Registration Program in 2019, allowing players access to a list of Financial Advisors affiliated with leading financial institutions. Institutional participants of the program are selected based on their industry capabilities and range of service offerings that meet the specific needs of NFL players. As an NFLPA Institutional Financial Advisor participant, Morgan Stanley Global Sports & Entertainment will have oversight of the Financial Advisors who will be designated to provide guidance to the members of the NFLPA."

10:00 EDT Bluegreen Vacations falls -14.1% - Bluegreen Vacations is down -14.1%, or -83c to $5.07.

10:00 EDT Teradata rises 13.5% - Teradata is up 13.5%, or $2.80 to $23.49.

10:00 EDT SailPoint rises 20.8% - SailPoint is up 20.8%, or $6.55 to $38.05.

09:47 EDT Horizon Global falls -10.1% - Horizon Global is down -10.1%, or -41c to $3.63.

09:47 EDT Alteryx falls -25.3% - Alteryx is down -25.3%, or -$42.74 to $126.26.

09:47 EDT Seritage Growth Properties rises 17.7% - Seritage Growth Properties is up 17.7%, or $1.82 to $12.10.

09:45 EDT InfuSystem trading halted, volatility trading pause

09:31 EDT CleanSpark, Sunshine Energy announce Costa Rica partnership - CleanSpark and Sunshine Energy announced the consummation of an exclusive partnership. The agreement allows Sunshine the exclusive right to market and sell CleanSpark's products and services throughout the country of Costa Rica. As part of the agreement, Sunshine will license mVSO energy modeling software for exclusive use in Costa Rica. Additionally, Sunshine agrees to procure all energy controls and energy storage systems directly through the Company. CleanSpark agrees to provide designated sales and consulting support to Sunshine, as well as favorable pricing for technical support services on all relevant projects.

09:28 EDT Diana Shipping announces time charter contract for m/v Melia - Diana Shipping announced that, through a separate wholly-owned subsidiary, it has entered into a time charter contract with Ausca Shipping Limited, Hong Kong, for one of its Panamax dry bulk vessels, the m/v Melia. The gross charter rate is $10,000 per day, plus $500,000 gross ballast bonus, minus a 5% commission paid to third parties, for a period of about eight months to maximum ten months. The charter is expected to commence on August 20, 2020. The "Melia" is a 76,225 dwt Panamax dry bulk vessel built in 2005. This employment is anticipated to generate approximately US$2.75 million of gross revenue for the minimum scheduled period of the time charter.

09:05 EDT Natera files additional patent infringement suit against ArcherDX - Natera filed suit yesterday against ArcherDX, Inc. for infringement of Natera's U.S. Patent No. 10,731,220. The complaint was filed in the U.S. District Court of Delaware. The '220 Patent is titled "Methods for Simultaneous Amplification of Target Loci" and was issued by the United States Patent and Trademark Office on August 4, 2020. The '220 Patent is one of more than 200 patents issued or pending in Natera's global intellectual property portfolio, including more than 60 in the field of oncology. Natera's complaint alleges that ArcherDX's sale and use of certain cell-free DNA-based oncology products infringes on the '220 Patent. In January of 2020, Natera filed suit in Delaware against ArcherDX (C.A. No. 20-125), asserting four additional patents. Natera is seeking injunctive relief and monetary damages in both cases.

09:01 EDT Tenable Holdings achieves FedRAMP 'In Process' designation - Tenable announced it has achieved the "In Process" designation from the Federal Risk and Authorization Management Program for its cloud-based vulnerability management platform, Tenable.io.

08:48 EDT Sina retains financial advisor and legal counsel for going private offer - Sina's independent special committee has retained Morgan Stanley Asia as its financial advisor, and Gibson, Dunn & Crutcher LLP as its U.S. legal counsel to assist the Special Committee in its evaluation and consideration of the previously announced preliminary non-binding proposal from New Wave that the Board received on July 6, proposing to acquire all the outstanding ordinary shares of the company not already owned by New Wave for $41 per share in cash in a going private transaction. New Wave is a company incorporated in the British Virgin Islands and controlled by Charles Chao, CEO of the company. No decisions have been made by the Special Committee with respect to the company's response to the Proposed Transaction.

08:41 EDT Waste Connections sees FY20 revenue down about 1% y/y

08:39 EDT Waste Connections on pace for 'solid' year of acquisition activity - Comments taken from Q2 earnings conference call.

08:35 EDT Ligand: CStone Pharma reports OmniAb-derived CS1001 trial met primary endpoint - Ligand Pharmaceuticals said in a release, "Ligand Pharmaceuticals announces CStone Pharmaceuticals recently reported that its OmniAb-derived anti-PD-L1 mAb CS1001 combined with platinum-based chemotherapy met its pre-specified primary endpoint, as assessed by the independent Data Monitoring Committee at the planned interim analysis of CS1001-302, a randomized, double-blind Phase 3 clinical trial for the first-line treatment of stage IV squamous and non-squamous NSCLC patients."

08:12 EDT Twin Disc to invest $7M-$9M in capex during FY21 - Jeffrey S. Knutson, Vice President - Finance, Chief Financial Officer, Treasurer and Secretary, stated: "Throughout the COVID-19 crisis we have aggressively eliminated expenses and aligned our cost structure with expected sales, while focusing on strengthening our balance sheet and reducing working capital levels. For fiscal year 2020 we generated $9.6 million of cash from operating activities, including $4.3 million of cash from operating activities during the fiscal 2020 fourth quarter. Working capital at June 30, 2020 was $107.2 million, compared to $127.3 million at June 30, 2019. Inventory reduction efforts contributed $5.3 million to this year-over-year improvement. We have deferred all non-essential spending and capital expenditures to conserve cash until the economic environment becomes clearer, and currently expect to invest $7 million to $9 million in capital expenditures during fiscal 2021."

08:07 EDT Senseonics announces Highmark coverage for Eversense CGM to begin in September - Senseonics announced Highmark will begin providing coverage for the Eversense CGM effective September 28. This coverage decision adds to the growing number of payers who are writing Eversense into their CGM coverage policies, as well as paying for the healthcare provider's time for the in-office sensor placement.

08:05 EDT Mill Road proposes to acquire Huttig Building Products for $2.75 per share - Mill Road Capital announced that it sent the following letter to the board of Huttig Building Products. "Mill Road Capital Management LLC and its affiliated funds ("Mill Road") are pleased to present this proposal for the acquisition of Huttig Building Products, Inc. ("Huttig" or the "Company"). As you know, Mill Road is one of the largest shareholders of Huttig with ownership of 8.1% of the Company's outstanding shares. Since making our initial investment in Huttig in 2017, we have developed a deep appreciation of the Company and its CEO, Jon Vrabely. Given our experience in the public markets, we recognize the inherent difficulties of creating value for shareholders as a public, micro-cap company. There is very little sell-side analyst coverage and minimal demand for micro-cap stocks. Institutional investors avoid stocks like Huttig; it is difficult to accumulate a position and any attempt to sell large blocks can materially depress the share price for months. As a result, microcaps often attract short-term shareholders who look for "quick wins" and actively dissuade management from making sensible investments in long-term value-creation. We hope that the Board of Directors finds this proposal compelling for the Company's shareholders and we look forward to working with you in connection with a transaction. Based on our review of publicly available information to date, Mill Road proposes to acquire 100% of the outstanding shares of the Company not already owned by Mill Road for $2.75 per share which represents a premium of 67% over today's closing price. The purchase price would be payable in cash. Given our familiarity with the Company and significant experience executing going-private transactions, we believe we can complete customary business, accounting, and legal due diligence and negotiate definitive documentation within 60 days.Mill Road anticipates the proposed transaction will be funded through a combination of third party debt in addition to equity capital provided by Mill Road. We have ample equity capital to complete the transaction and are highly confident in our ability to raise an appropriate amount of debt financing."

08:05 EDT Global Blood Therapeutics announces new employment inducement grants - Global Blood Therapeutics announced that on August 1, 2020, the compensation committee of GBT's board of directors granted seven new employees options to purchase an aggregate of 9,750 shares of the company's common stock with a per share exercise price of $67.48 and restricted stock units for an aggregate of 55,675 shares of the company's common stock. These awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan (the Plan). Pursuant to the Plan, the exercise price for the 9,750 shares of the company's common stock was the closing trading price on July 31, 2020, because there was no closing trading price on August 1, 2020.

08:01 EDT PriceSmart reports July merchandise sales up 2.2% y-o-y - PriceSmart announced July net merchandise sales up 2.2% to $261.4M from $255.8M in July a year earlier. Foreign currency exchange fluctuations impacted net merchandise sales negatively by 3.7% or $9.6M versus the same one-month period in the prior year. There were 46 warehouse clubs in operation at the end of July 2020 and 43 warehouse clubs in operation at the end of July 2019. Comparable net merchandise sales for the 42 warehouse clubs open at least 13 1/2 full months decreased 4.5% when compared to the same four-week period last year. Foreign currency exchange rate fluctuations impacted comparable net merchandise sales negatively by 3.6% or $8.3M versus the same period in the prior year.

07:46 EDT Sabre sees $275M in cost savings in 2020 - "Our thoughts continue to be with those around the world impacted by the COVID-19 pandemic," said Doug Barnett, CFO. "We continue to take the cost actions necessary in this difficult environment, including a recently signed contract extension with DXC that provides significant savings over its multi-year term. We remain committed to our expectation for approximately $275 million in 2020 cost savings and are working aggressively to position ourselves for growth post-COVID-19."

07:46 EDT Arbutus entitled to receive tiered low single digit royalties on Genevant sales - On July 23, 2020, the United States Patent and Trademark Office before the Patent Trial and Appeal Board announced their decision in Moderna Therapeutics, Inc.'s challenge of the validity of U.S. Patent 8,058,069. In this decision, the PTAB determined no challenged claims were unpatentable. While Arbutus is the patent holder, this patent has been licensed to Genevant. The '069 Patent was included in this license agreement between Genevant and Arbutus. Arbutus is gratified by the recent decision of the PTAB, upholding the validity of one of the patents protecting Arbutus' LNP technology that Arbutus licensed to Genevant. This decision reinforces Arbutus' continuing belief in the potential of this technology. Arbutus is entitled to receive tiered low single digit royalties on future sales of Genevant products covered by the licensed patents. If Genevant sub-licenses the intellectual property licensed by Arbutus to Genevant, Arbutus would receive upon the commercialization of a product developed by such sub-licensee the lesser of twenty percent of the revenue received by Genevant for such sublicensing and tiered low single digit royalties on product sales by the sublicensee. On July 31, 2020, Roivant recapitalized Genevant through an equity investment and conversion of previously issued convertible debt securities held by Roivant. Arbutus participated in the recapitalization of Genevant with an equity investment of $2.5 million. Following the recapitalization, Arbutus owns approximately 16% of the common equity of Genevant. Arbutus' entitlement to receive future royalties or sublicensing revenue from Genevant remains unchanged.

07:44 EDT Sabre CEO says 'overall travel environment remains severely depressed' - "This remains an extraordinary time of disruption in global travel. As a mission-critical solutions provider to the global travel industry, we responded quickly and effectively to reduce costs and improve liquidity to mitigate the massive challenge the COVID-19 pandemic represents. We took difficult and decisive actions that we believe best position the company on the other side of this crisis," said Sean Menke, President and CEO. "Although we exited the quarter with positive net air bookings in June for the first time since early March and stronger improvement in hotel bookings, the overall travel environment remains severely depressed. The COVID-19 pandemic has caused major shifts in the travel ecosystem. We have taken this opportunity to right-size our global organization with a reduction in workforce and accelerate the realignment of our airline and agency-focused businesses to provide a stronger, more seamless experience for our customers. We are winning new business and signing key renewals even during this challenging time. Because of the progress we've made on our cloud migration, we have successfully scaled down processing capacity during this time of reduced travel volumes, resulting in significantly lower technology costs. We are accelerating our transition to Google Cloud and have completed the necessary integration work to start migrating workloads in the second half of 2020."

07:44 EDT Arbutus Biopharma expects to complete IND-enabling studies of AB-836 by year-end - In January 2020, Arbutus selected AB-836 as its next-generation oral capsid inhibitor. AB-836 is from a novel chemical series differentiated from Arbutus' second generation capsid inhibitor candidate, AB-506, as well as competitor compounds. AB-836 has the potential for increased potency and an enhanced resistance profile as compared to AB-506. Arbutus continues to expect completion of IND-enabling studies by the end of 2020.

07:41 EDT Arbutus Biopharma expects cash to fund operations into mid-2022 - Arbutus had cash, cash equivalents and investments totaling $84.0 million as of June 30, 2020, as compared to $90.8 million as of December 31, 2019. During the six months ended June 30, 2020, Arbutus used $24.3 million in operating activities, which was partially offset by $17.4 million of net proceeds from the issuance of common shares under Arbutus's ATM program. During July 2020, Arbutus fully utilized the remaining availability under the ATM program resulting in an additional $36.5 million of net proceeds from the issuance of 9.5 million common shares. The Company believes its ending second quarter cash, cash equivalents and investments of $84.0 million plus the additional $36.5 million of proceeds received under the ATM program during July 2020 are sufficient to fund the Company's operations into mid-2022 versus prior guidance of mid-2021.

07:36 EDT Biogen jumps 10% to $305 after FDA accepts aducanumab with priority review

07:33 EDT Biogen's aducanumab assigned PDUFA target action date of March 7, 2021

07:32 EDT E.W. Scripps suspends issuing new guidance - Scripps has suspended issuing new guidance because of the economic uncertainty caused by the COVID-19 pandemic.

07:23 EDT Aclaris Therapeutics to submit IND for ATI-2138 in 2021 - Aclaris is developing ATI-2138 as a potential treatment for psoriasis and/or inflammatory bowel disease and expects to submit an IND for ATI-2138 in 2021.

07:22 EDT Aclaris Therapeutics to progress to first-in-human trial of ATI-1777 - Aclaris submitted an Investigational New Drug Application for ATI-1777 for the treatment of moderate to severe atopic dermatitis in June 2020 and now plans to progress to the first-in-human trial of ATI-1777 in subjects with moderate to severe AD.

07:20 EDT Aclaris Therapeutics sees data from ATI-450-RA-201 trial in 1H21 - ATI-450-RA-201: An ongoing Phase 2a trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450 in subjects with moderate to severe rheumatoid arthritis. This trial was initiated in March 2020. Due to the COVID-19 pandemic, Aclaris temporarily paused enrollment. Aclaris resumed enrolling subjects, and the first subject was dosed, in May 2020. At this time, Aclaris is actively recruiting for this trial. Given the continuing evolution of the COVID-19 pandemic, Aclaris now anticipates reporting data from this trial in the first half of 2021.

07:16 EDT Replimune Group to present intial data from Phase 1 RP2 trial by end of 2020 - The Company plans to present initial safety and efficacy data from the ongoing Phase 1 clinical trial evaluating RP2 alone and in combination with Opdivo by the end of 2020.

07:14 EDT Replimune Group currently enrolling patients in refractory melanoma trial - RP1 in combination with Opdivo in anti-PD-1 refractory melanoma: The Company initiated recruitment into a new registration-directed 125-patient cohort in the Phase 2 clinical trial of RP1 in combination with Opdivo in February 2020 and is currently enrolling patients.

07:12 EDT Replimune expects to open CSCC trial sites in Canada, Europe later this year - RP1 in combination with Libtayo in cutaneous squamous cell carcinoma: The Company is actively enrolling patients into the 240-patient registration-directed Phase 2, randomized, controlled clinical trial in the US and Australia, with clinical trial sites in Canada and Europe expected to open later in the year.

07:08 EDT Greenlane to close Jacksonville, Torrance distribution centers in Q3 - In connection with the Company's business transformation initiative and ongoing efforts to optimize its distribution network, Greenlane continues to transition to a more streamlined and centralized model with fewer, but larger, highly automated distribution facilities. In the second quarter of 2020, the Company completed the closings of its Schenectady, NY and Delta, Canada distribution centers. In June 2020, the Company terminated the lease agreements for its Torrance, CA distribution center and Toronto, Canada office location, and plan to close its Jacksonville, FL and Visalia and Torrance, CA distribution centers in the third quarter of 2020.

07:06 EDT AGM Group Holdings signs LOI to acquire Hong Kong-based Safe Gold Financial - AGM Group Holdings, through its wholly-owned subsidiary, AGM Technology, has entered into a letter of intent with the shareholders of Safe Gold Financial to acquire 100% equity interest in Safe Gold and its wholly owned subsidiary Safe Gold Securities and Futures. Safe Gold is a Hong Kong-based financial services company which, through its wholly-owned subsidiary Safe Gold SF, holds Hong Kong Financial Services Licenses Type 1 - Dealing of Securities -, Type 2 - Dealing in Futures Contracts -, Type 4 - Advertising on Securities -, Type 5 - Advertising on Futures Contracts -, and Type 9 - Asset Management -. Total consideration of the proposed all-cash transaction is set to equal the combined net asset value for Safe Gold and Safe Gold SF as of June 30 plus a premium of HK$8.5M, deducting a due from shareholders of HK$14M, subject to certain adjustments and definitive agreements at the closing.

07:05 EDT Aclaris Therapeutics expects cash to be sufficient through 1Q22 - Aclaris anticipates that its cash, cash equivalents and marketable securities as of June 30, 2020 will be sufficient to fund its operations through the first quarter of 2022, without giving effect to any potential business development transactions or financing activities.

07:03 EDT Replimune expects cash, cash equivalents to fund requirements into mid-2023 - As of June 30, 2020, cash, cash equivalents and short-term investments were $261.8 million, as compared to $168.6 million as of March 31, 2020. This increase was primarily related to $109.5 million in net proceeds from financing activities offset by cash utilized in fiscal quarter one operating activities largely associated with advancing our expanded clinical development plan. The Company believes that the existing cash and cash equivalents and short-term investments, along with a limited use of debt, will enable the Company to fund additional studies and the overall operating plan to mid-2023.

06:59 EDT Ventas lowers FY20 CapEx view to approximately $0.5B from $0.8B - The company expects to fund remaining 2020 development and redevelopment capital expenditures through committed financing.

06:41 EDT Summit Midstream sees FY20 adjusted EBITDA $250M-$260M

06:36 EDT Jounce Therapeutics sees cash and investments sufficient through end of 2021 - Jounce continues to expect gross cash burn on operating expenses and capital expenditures for the full year 2020 to be approximately $80.0M-$95.0M. Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the end of 2021.

06:10 EDT Consolidated Communications awarded $3.5M in grants from New Hampshire - Consolidated Communications announced plans to partner with the state of New Hampshire and local towns to invest nearly $18M to expand and enhance broadband services across the state. Consolidated was awarded $3.5M in grants from the state's Connecting New Hampshire - Emergency Broadband Expansion Program to build high-speed, fiber-to-the-premises Internet networks to homes and businesses in Danbury, Springfield, and Mason. The company also received a separate grant to upgrade existing Internet services in the town of Errol. These grants will provide new and enhanced Internet services to more than 2,500 residents and businesses in New Hampshire. Consolidated will invest nearly $1.5M to support these projects.

06:09 EDT Northern Oil and Gas sees 2020 production 30K-40K BOE/day - Sees CapEx for the second half of 2020 $50M-$75M and 2020 CapEx $175M-$200M.

06:01 EDT Baker Hughes announces July international rig count of 743, down 38 - Baker Hughes announced that the Baker Hughes international rig count for July 2020 was 743 down 38 from the 781 counted in June 2020, and down 419 from the 1,162 counted in July 2019. The international offshore rig count for July 2020 was 183, down 11 from the 194 counted in June 2020, and down 72 from the 255 counted in July 2019. The average U.S. rig count for July 2020 was 255, down 19 from the 274 counted in June 2020, and down 700 from the 955 counted in July 2019. The average Canadian rig count for July 2020 was 32, up 14 from the 18 counted in June 2020, and down 89 from the 121 counted in July 2019. The worldwide rig count for July 2020 was 1,030, down 43 from the 1,073 counted in June 2020, and down 1,208 from the 2,238 counted in July 2019.

05:58 EDT Trump issues executive order banning TikTok, Tencent's WeChat in U.S. - President Trump said last night in an executive order, "As I explained in an Executive Order of August 6, 2020 (Addressing the Threat Posed by Tiktok, and Taking Additional Steps to Address the National Emergency With Respect to the Information and Communications Technology and Services Supply Chain), the spread in the United States of mobile applications developed and owned by companies in the People's Republic of China (China) continues to threaten the national security, foreign policy, and economy of the United States. To protect our Nation, I took action to address the threat posed by one mobile application, TikTok. Further action is needed to address a similar threat posed by another mobile application, WeChat. WeChat, a messaging, social media, and electronic payment application owned by the Chinese company Tencent Holdings Ltd., reportedly has over one billion users worldwide, including users in the United States. Like TikTok, WeChat automatically captures vast swaths of information from its users. This data collection threatens to allow the Chinese Communist Party access to Americans' personal and proprietary information. In addition, the application captures the personal and proprietary information of Chinese nationals visiting the United States, thereby allowing the Chinese Communist Party a mechanism for keeping tabs on Chinese citizens who may be enjoying the benefits of a free society for the first time in their lives...The following actions shall be prohibited beginning 45 days after the date of this order, to the extent permitted under applicable law: any transaction that is related to WeChat by any person, or with respect to any property, subject to the jurisdiction of the United States, with Tencent Holdings." Reference Link

05:28 EDT Magna says COVID-19 resulted in loss of sales of ~$5.5B - Magna said in its Q2 earnings release, "During the second quarter of 2020, our most significant production markets of North America and Europe experienced vehicle production declines compared to the second quarter of 2019 that, both in percentage and absolute volume terms, far exceeded the worst comparable quarterly declines experienced during the 2008-2009 financial crisis. These declines are largely due to our customers' production suspensions and volume reductions attributable to the COVID-19 pandemic. Based on our expectations at the beginning of the year, we estimate that reduced volumes in the quarter resulted in lost sales of approximately $5.5 billion and that Adjusted EBIT was negatively impacted by approximately $1.2 billion. For the six months ended June 30, we estimate such lost sales to be approximately $6.6 billion and that Adjusted EBIT was negatively impacted by approximately $1.45 billion. (Loss) income from operations before income taxes, net (loss) income attributable to Magna International Inc. and diluted (loss) earnings per share, each for the second quarter and six months ended June 30, were also negatively impacted by the COVID-19 related volume reductions."

05:23 EDT Magna reports Q2 global light vehicle production down 42% - Magna reports Q2 North America light vehicle production down 79%. Reports Q2 Europe light vehicle production down 59%.